Atlas
Back to RCM
Peer Fund / Dealmaker·RCM

Adam Abramson

Partner at Audax Private Equity

Boston, Massachusetts

AA
Why they matter

Audax's healthcare partner since 2000; he underwrote Elevate PFS in revenue cycle and exited urology and ABA platforms, giving live pattern recognition on healthcare buy-and-build.

Background

Adam A. Abramson is a Partner at Audax Private Equity, which he joined in 2000, making him one of the firm's longest-tenured investment professionals. He has invested in roughly 40 platform companies across healthcare, consumer, and software/technology, and is a central figure in Audax's healthcare specialization and its Buy & Build strategy. Prior to Audax he was at Thomas H. Lee Partners working on leveraged buyouts across industries, and before that in Morgan Stanley & Co.'s real estate principal investment group; he holds an A.B. from Harvard College.

Notable deals

  • 2025
    Quoted as the Audax partner on the firm's strategic investment (with Parthenon Capital) in Elevate Patient Financial Solutions, an eligibility and enrollment specialist expanding into back-end revenue cycle management for hospitals and health systems; closed July 31, 2025.
  • 2024
    Audax partner voice on the sale of United Urology Group — a ~250-provider urology network across Arizona, Colorado, Delaware, Maryland and Tennessee — to OneOncology, announced August 2024.
  • 2025
    Led commentary on Audax's completed exit of Proud Moments ABA to Nautic Partners (February 3, 2025), which he framed as the second realization out of the firm's healthcare specialization in six months.
  • 2024
    Quoted as the Audax partner on the firm's alternative practice structure investment in accounting firm Doeren Mayhew, announced August 23, 2024, to fund organic growth and acquisition-led geographic expansion.

Call-prep brief

Background

  • Partner at Audax Private Equity; joined in 2000, one of the firm's longest-tenured investors.
  • Roughly 40 platform investments across healthcare, consumer, and software/technology.
  • Prior: Thomas H. Lee Partners (LBOs) and Morgan Stanley & Co.'s real estate principal investment group. A.B., Harvard College.

Current focus

  • Healthcare services and healthcare IT inside Audax's Flagship Buy & Build strategy, with a visible tilt toward revenue cycle.
  • Led Audax's July 2025 investment in Elevate Patient Financial Solutions alongside Parthenon Capital — a front-end eligibility and enrollment leader pushing into back-end RCM.

What he cares about

  • Stated thesis: back companies that improve access to care and patient outcomes while reducing cost for payors and the healthcare system at large.
  • Add-on M&A as the primary value-creation lever, not multiple arbitrage — he explicitly credits the Buy & Build strategy for value creation on exit.
  • Cadence of realizations out of the healthcare vertical; he tracks and publicly frames them.

Recent moves

  • Aug 2024: sale of United Urology Group to OneOncology.
  • Aug 2024: Doeren Mayhew alternative practice structure investment (shows he works outside healthcare too).
  • Feb 2025: exit of Proud Moments ABA to Nautic Partners.
  • Jul 2025: Elevate PFS investment closed.

Potential sensitivities

  • Elevate is a live, unexited position — expect guarded answers on pricing, growth rates, and the add-on pipeline.
  • PE ownership of physician practices (urology, ABA therapy) attracts policy and press scrutiny; raise it neutrally, not as a challenge.

Three questions to ask

  1. Where does front-end eligibility and enrollment stop being defensible as payers automate more of it?
  2. What did the United Urology and Proud Moments exits teach you about who is actually buying provider-adjacent assets today?
  3. In RCM add-ons specifically, which integration failure has cost you the most value?

Outreach draft

Subject
Elevate PFS and the RCM buy-and-build path
Hi Adam — I'm building a view on healthcare revenue cycle, and Audax's Elevate PFS investment is the clearest recent statement I've seen on where front-end eligibility meets back-end RCM. Two things I'd value your read on: how you underwrite durability in eligibility and enrollment as payers automate more of it, and what the United Urology and Proud Moments exits told you about who is genuinely buying provider-adjacent assets right now. I'm not pitching anything — just want a sharper thesis before we commit diligence resources, and you've seen more cycles in this vertical than almost anyone. Would twenty minutes in the next few weeks work? Best, [Your Name]

Linked companies

Sources